Infectious Disease Vaccine Platform License

Eli Lilly and Company (LLY) entered into a research and licensing agreement with Amplitude Therapeutics on August 19, 2026, for trans-amplifying RNA (taRNA) vaccine technology. The initial program targets infectious diseases with high unmet medical needs, and Lilly has an option to add up to two additional infectious disease targets. Brand names, generic names, and pathogen antigens for specific candidates have not yet been designated, and the development stage is in candidate identification and preclinical phases. A key aspect of the deal is Lilly's acquisition of a platform that allows for the repeated production of multiple vaccines, rather than a single asset.

Separation of Replicase and Antigen in Design

Amplitude's taRNA delivers the replicase sequence, responsible for RNA replication, and the pathogen antigen sequence in separate RNA strands. Unlike self-amplifying mRNA (sa-mRNA), which combines replicase and antigen in a single long molecule, taRNA is designed to allow independent optimization of antigen switching, formulation, and dosing. Amplitude will be responsible for taRNA optimization and agreed preclinical studies, while Lilly will handle subsequent preclinical, clinical, manufacturing, regulatory, and commercial activities. However, low-dose administration and manufacturing improvements are the current design goals, and there are no efficacy data proven through human clinical trials yet.

Regulatory Pathways from Precedent Approval

The most direct technological competitor is Kostaive by Arcturus Therapeutics (ARCT) and CSL Limited (CSL), with the brand name Kostaive and the generic name zapomeran, targeting the SARS-CoV-2 spike protein. This sa-mRNA vaccine was approved in Japan in November 2023 and received marketing authorization in the European Union for adult use in February 2025, entering the Marketed stage. Established competitors in the standard category include Comirnaty by Pfizer (PFE) and BioNTech (BNTX), and Spikevax by Moderna (MRNA), which are non-amplifying mRNA vaccines. The approval of the preceding product has opened a regulatory pathway for amplifying RNA, but Lilly and Amplitude's program is still preclinical, so platform superiority must be compared through clinical data.

Rights Structure and Commercial Implications

Lilly receives exclusive rights to develop and commercialize candidates for each partnered target, while Amplitude is responsible for initial technology optimization. The upfront, milestone, royalty, and equity amounts and allocations are not disclosed in the press release, so deal_value is null. 360iResearch estimates the global infectious disease vaccine market at USD 34.88 billion in 2025 and USD 38.23 billion in 2026, providing a sufficient commercial foundation for platform expansion. For Lilly, this is a long-term option outside its obesity and diabetes-focused revenue structure, and for Amplitude, it is an opportunity to validate its taRNA technology within a global development and manufacturing system since its founding in 2022.